| Date | Title | Description |
| 14.02.2019 | MedImmune brand to be retired as biologics integrate into AstraZeneca’s new R&D structure | MedImmune brand to be retired as biologics integrate into AstraZeneca’s new R&D structure
14-02-2019
MedImmune today announced that its corporate brand will be retired as biologics are integrated into AstraZeneca’s two new research and ... |
| 17.09.2018 | Here’s a look at Maryland’s publicly-traded biotech companies | When talk turns to Maryland’s biotech bonafides, the ideas and talent being produced by government institutions like NIH, and research-oriented universities with connected health systems such as Johns Hopkins and University of Maryland are ... |
| 04.05.2018 | Cambridge life sciences cluster set to deliver additional £1billion to the UK economy by 2032 | Cambridge life sciences cluster set to deliver additional £1billion to the UK economy by 2032
04-05-2018
The Cambridge life sciences cluster has the potential to contribute an additional £1bn to the UK economy by 2032, according to independ... |
| 04.08.2017 | Big Pharma veterans at Pfizer, AstraZeneca join the great migration to biotech | → Biogen has recruited Anabella Villalobos as its new SVP of biotherapeutic & medicinal sciences. The neurosciences vet was poached from Pfizer, where she was head of medicinal synthesis technologies.
→ Jean-C... |
| 25.05.2017 | Medimmune and UTC Cambridge complete third student Challenge Project | Medimmune and UTC Cambridge complete third student Challenge Project
25-05-2017
MedImmune, the global biologics research and development arm of AstraZeneca, and University Technical College (UTC) Cambridge have completed an eight-week ‘Chal... |
| 01.05.2017 | AstraZeneca's bladder cancer drug gets FDA approval | AstraZeneca's bladder cancer drug gets FDA approval
01-05-2017
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to ... |
| 01.05.2017 | AstraZeneca's bladder cancer drug gets FDA approval | AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Imfinzi (durvalumab).
Add This Share Buttons
Imfinzi is indicat... |
| 30.11.2016 | MedImmune and universities consortium awarded 12 BBSRC biotechnology PhD studentships | MedImmune and universities consortium awarded 12 BBSRC biotechnology PhD studentships
30-11-2016
MedImmune, the global biologics research and development arm of AstraZeneca, and a consortium of universities — the Universities of Cambridge, ... |
| 29.11.2016 | AstraZeneca spins out a bispecific antibody into a new cancer biotech with partner AbPro | Jane Osbourn, MedImmune
AstraZeneca’s big subsidiary MedImmune and synthetic biology player AbPro are joining forces on a spin-out company which will undertake the development of a preclinical bispecific antibod... |
| 03.10.2016 | MedImmune out-licenses potential medicine for inflammatory diseases to Allergan | MedImmune out-licenses potential medicine for inflammatory diseases to Allergan
03-10-2016
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Allergan p... |
| 18.05.2016 | AstraZeneca announces positive results for potential new medicine for asthma | AstraZeneca has announced that benralizumab, a potential new medicine and anti-eosinophil monoclonal antibody, was well tolerated and achieved the primary endpoint in two pivotal Phase III registrational trials (SIROCCO and CALIMA), demonst... |
| 18.05.2016 | AstraZeneca announces positive results for potential new medicine for asthma | AstraZeneca announces positive results for potential new medicine for asthma
18-05-2016
AstraZeneca has announced that benralizumab, a potential new medicine and anti-eosinophil monoclonal antibody, was well tolerated and achieved the prima... |
| 22.04.2016 | AstraZeneca launches integrated genomics approach to drug discovery and development | AstraZeneca and its global biologics research and development arm, MedImmune, today announced an integrated genomics initiative to transform drug discovery and development across its entire research and development pipeline.
The initiative ... |
| 22.04.2016 | AstraZeneca launches integrated genomics approach to drug discovery and development | AstraZeneca launches integrated genomics approach to drug discovery and development
22-04-2016
AstraZeneca and its global biologics research and development arm, MedImmune, today announced an integrated genomics initiative to transform drug... |
| 09.03.2016 | MedImmune receives fast track designation in the US for influenza antibody | MedImmune receives fast track designation in the US for influenza antibody
09-03-2016
AstraZeneca has announced that its global biologics research and development arm, MedImmune, has received Fast Track designation from the US Food and Drug... |
| 09.03.2016 | MedImmune receives fast track designation in the US for influenza antibody | AstraZeneca has announced that its global biologics research and development arm, MedImmune, has received Fast Track designation from the US Food and Drug Administration (FDA) for its investigational human monoclonal antibody (mAb), MEDI885... |
| 12.01.2016 | AstraZeneca and Moderna Therapeutics announce new collaboration | AstraZeneca and Moderna Therapeutics announce new collaboration
12-01-2016
AstraZeneca, along with its global biologics research and development arm, MedImmune, and Moderna Therapeutics have announced a new collaboration to discover, co-dev... |
| 11.12.2015 | AstraZeneca to harness power of the Secretome and develop next-generation biologics | AstraZeneca to harness power of the Secretome and develop next-generation biologics
11-12-2015
AstraZeneca and its global biologics research and development arm, MedImmune, today announced a three-year collaboration with the newly establish... |
| 14.10.2015 | Human Vaccines Project partners with MedImmune | Human Vaccines Project partners with MedImmune
14-10-2015
MedImmune is the newest member of the Human Vaccines Project, which will help to accelerate the research and development of vaccines and immunotherapies for infectious disease and ca... |
| 25.09.2015 | MedImmune and Tanabe Research Laboratories have entered into a strategic collaboration | MedImmune and Tanabe Research Laboratories have entered into a strategic collaboration
25-09-2015
MedImmune, the global biologics research and development arm of AstraZeneca, and Tanabe Research Laboratories U.S.A., Inc. (TRL), a subsidiary... |
| 25.08.2015 | AstraZeneca and Peregrine to collaborate on immuno-oncology combination clinical trial | AstraZeneca and Peregrine to collaborate on immuno-oncology combination clinical trial
25-08-2015
AstraZeneca today announced that it has entered into a clinical trial collaboration with Peregrine Pharmaceuticals, Inc. to evaluate the safet... |
| 06.07.2015 | Dr Jane Osbourn joins Babraham Bioscience Technologies as new Non-Executive Director | Dr Jane Osbourn joins Babraham Bioscience Technologies as new Non-Executive Director
06-07-2015
Babraham Bioscience Technologies Ltd (BBT), which develops and manages the Babraham Research Campus, announced today that Dr Jane Osbourn, VP R&... |
| 30.06.2015 | AstraZeneca-University of Cambridge announce joint PhD and clinical research scholarships | AstraZeneca-University of Cambridge announce joint PhD and clinical research scholarships
30-06-2015
AstraZeneca and the University of Cambridge today announced three new joint schemes to support more than 80 PhD scholarships and eight clin... |
| 27.05.2015 | MedImmune and University of Cambridge strengthen partnership | MedImmune and University of Cambridge strengthen partnership
27-05-2015
MedImmune, the global biologics research and development arm of AstraZeneca, and the University of Cambridge have announced a new five-year, multi-project collaboration... |
| 14.05.2015 | AstraZeneca updates on immuno-oncology pipeline and combination treatments at ASCO 2015 | AstraZeneca updates on immuno-oncology pipeline and combination treatments at ASCO 2015
14-05-2015
AstraZeneca and MedImmune, the Company’s global biologics research and development arm, will demonstrate rapid progress with their combinatio... |
| 09.04.2015 | MedImmune's MEDI8897 receives fast track designation by the FDA | MedImmune's MEDI8897 receives fast track designation by the FDA
09-04-2015
MedImmune, the global biologics research and development arm of AstraZeneca, announced today that it has received fast track designation from the US Food and Drug Ad... |
| 09.04.2015 | MedImmune's MEDI8897 receives fast track designation by the FDA | MedImmune, the global biologics research and development arm of AstraZeneca, announced today that it has received fast track designation from the US Food and Drug Administration (FDA) for the development of MEDI8897.
This high-potency, exte... |
| 20.03.2015 | MedImmune establishes collaboration with São Paulo Research Foundation, Brazil | MedImmune establishes collaboration with São Paulo Research Foundation, Brazil
20-03-2015
MedImmune and São Paulo Research Foundation (FAPESP) in Brazil will invest up to $2 million each to fund selected projects in cardiovascular and metab... |
| 10.03.2015 | MedImmune and Joslin Diabetes Center collaborate on advancing metabolic disease research | MedImmune and Joslin Diabetes Center collaborate on advancing metabolic disease research
10-03-2015
MedImmune, the global biologics research and development arm of AstraZeneca, and Joslin Diabetes Center, the world's largest diabetes resear... |
| 20.02.2015 | MedImmune and NIST partner to advance development of biological therapies | MedImmune and NIST partner to advance development of biological therapies
20-02-2015
MedImmune, the global biologics research and development arm of AstraZeneca, and the US Department of Commerce’s National Institute of Standards and Techno... |
| 03.02.2015 | Combacte-Magnet: another new project to revitalise antibotic development | Combacte-Magnet: another new project to revitalise antibotic development
03-02-2015
Today 33 European academic partners and five pharmaceutical companies are launching a new project, COMBACTE-MAGNET, under the IMI antimicrobial resistance r... |
| 02.02.2015 | First patient enrolled in the new Drugs 4 Bad Bugs Programme | First patient enrolled in the new Drugs 4 Bad Bugs Programme
02-02-2015
Two years after the start of the Innovative Medicines Initiative (IMI)-funded New Drugs 4 Bad Bugs (ND4BB) programme, the first patient has been enrolled into a Phase 2... |
| 17.11.2014 | MedImmune presents promising new data in systemic lupus | MedImmune presents promising new data in systemic lupus
17-11-2014
MedImmune, the global biologics research and development arm of AstraZeneca, today announced it will be presenting positive data from a Phase IIb study on sifalimumab, a nov... |
| 17.11.2014 | MedImmune presents positive Phase IIB data for rheumatoid arthritis treatment | MedImmune presents positive Phase IIB data for rheumatoid arthritis treatment
17-11-2014
MedImmune, the global biologics research and development arm of AstraZeneca, today announced positive results from a Phase IIb study of mavrilimumab, a... |
| 08.10.2014 | MedImmune in-licenses acute coronary syndrome biologic research program from Shionogi | MedImmune in-licenses acute coronary syndrome biologic research program from Shionogi
08-10-2014
MedImmune, the global biologics research and development arm of AstraZeneca, and Japanese drug discovery-based pharmaceutical company Shionogi ... |
| 05.06.2014 | MedImmune and Ventana Medical Systems, Inc. collaborate for immunotherapy clinical trials | MedImmune and Ventana Medical Systems, Inc. collaborate for immunotherapy clinical trials
05-06-2014
MedImmune, the global biologics research and development arm of AstraZeneca, and Ventana Medical Systems, Inc., a member of the Roche Group... |
| 15.05.2014 | AstraZeneca to demonstrate strength of its oncology pipeline at ASCO | AstraZeneca to demonstrate strength of its oncology pipeline at ASCO
15-05-2014
New data from AstraZeneca’s investigational cancer medicines demonstrate the rapid progression of its oncology pipeline. Over 40 scientific abstracts from Astra... |
| 13.05.2014 | Key MedImmune molecules meet primary endpoints in Phase II studies | Key MedImmune molecules meet primary endpoints in Phase II studies
13-05-2014
AstraZeneca announced that two key molecules in MedImmune’s Respiratory, Inflammation and Autoimmune (RIA) portfolio – mavrilimumab and sifalimumab – met their pr... |
| 13.05.2014 | AstraZeneca to present respiratory data at ATS 2014 International Conference | AstraZeneca to present respiratory data at ATS 2014 International Conference
13-05-2014
Benralizumab and tralokinumab data both show improvement in key measures of asthma control for patients with specific, severe forms of asthma.
Data unde... |
| 08.05.2014 | AstraZeneca initiates phase III immunotherapy study for MEDI4736 in patients with lung cancer | AstraZeneca initiates phase III immunotherapy study for MEDI4736 in patients with lung cancer
08-05-2014
AstraZeneca today announced the start of the Phase III programme for MEDI4736, an immunotherapy in development for the treatment of non... |
| 30.04.2014 | MedImmune expands University System of Maryland research collaboration | MedImmune expands University System of Maryland research collaboration
30-04-2014
MedImmune, the global biologics research and development arm of AstraZeneca, and the University System of Maryland announced that the initial research collabo... |
| 30.04.2014 | MedImmune expands University System of Maryland research collaboration | MedImmune, the global biologics research and development arm of AstraZeneca, and the University System of Maryland announced that the initial research collaboration between MedImmune and the University of Maryland, Baltimore (UMB) has been ... |
| 14.03.2014 | MedImmune and MD Anderson join forces to advance cancer immunotherapy | MedImmune and MD Anderson join forces to advance cancer immunotherapy
14-03-2014
MedImmune, AstraZeneca’s global biologics research and development arm, announced it has entered into a three-year translational and clinical research collabor... |
| 09.01.2014 | MedImmune and Immunocore enter immunotherapy agreement to develop novel cancer therapies | MedImmune and Immunocore enter immunotherapy agreement to develop novel cancer therapies
09-01-2014
AstraZeneca has announced that MedImmune, its global biologics research and development arm, has entered into an oncology research collabora... |
| 26.11.2013 | MedImmune celebrates 25 years of biotech innovation | MedImmune celebrates 25 years of biotech innovation
26-11-2013
MedImmune, the global biologics research and development arm of AstraZeneca, is celebrating its 25th anniversary with a donation to Macmillan Cancer Support.
MedImmune was found... |
| 12.11.2013 | MedImmune scientist wins Royal Society of Chemistry Education Award | MedImmune scientist wins Royal Society of Chemistry Education Award
12-11-2013
MedImmune, the global biologics research and development arm of AstraZeneca, is pleased to congratulate Dr Monika Papworth, a scientist based at the company’s Ca... |
| 31.10.2013 | AstraZeneca advances Medimmune's benralizumab to Phase III in severe asthma | AstraZeneca advances Medimmune's benralizumab to Phase III in severe asthma
31-10-2013
AstraZeneca has announced the start of the Phase III Windward programme for benralizumab, a potential treatment for severe uncontrolled asthma developed ... |
| 16.10.2013 | MedImmune Cambridge supports Society of Biology’s ‘Big Biology Day’ | MedImmune Cambridge supports Society of Biology’s ‘Big Biology Day’
16-10-2013
MedImmune Cambridge was pleased to support the Society of Biology’s ‘Big Biology Day’ at Hills Road Sixth Form College on Saturday 12 October 2013, held in partn... |
| 15.10.2013 | MedImmune and Auven invest USD 40 million in ADC Therapeutics | |
| 03.09.2013 | Inspiring the next wave of bio innovation | Inspiring the next wave of bio innovation
03-09-2013
The forthcoming 'Beating the odds in biobusiness’ conference gains sponsorship from big pharma to inspire and encourage young and emerging biobusinesses.
Conference partners Miranda Westo... |
| 18.06.2013 | MedImmune and NGM Biopharmaceuticals link for research on diabetes and obesity | MedImmune and NGM Biopharmaceuticals link for research on diabetes and obesity
18-06-2013
AstraZeneca today announced that MedImmune, its global biologics research and development arm, and NGM Biopharmaceuticals, Inc. have entered into an e... |
| 18.03.2013 | AstraZeneca shakes up R&D division with 1,600 staff cuts and shift to biotech hot spots (video) | The pharmaceutical company said shifting its R&D sites to “bioscience hot spots” will make it easier to develop collaboration and partnership agreements. It will also help teams work more closely “to create a more vibrant environment” t... |
| 25.07.2012 | Biopharmaceutical firm NuPathe co-founder and CEO exits, enter former Auxilium head | Incoming CEO and board member Armando Anido has 30 years of experience in the pharmaceutical industry most recently as president and CEO of Auxilium Pharmaceuticals. During his six-year tenure there he helped grow market capitalization from... |
| 02.04.2012 | Former head of Sanofi vaccines division becomes infectious disease biotech CEO | Last year, it was granted a five-year research grant valued up to $196 million by the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services, to fund the development of seasonal and ... |
| 13.12.2011 | Catabasis Pharmaceuticals Raises $8M in Extended Series A Financing | Catabasis Pharmaceuticals, a Cambridge, Mass.-based clinically staged company dedicated to the discovery and development of innovative, effective and safe medicines to treat inflammatory and metabolic diseases, has raised further $8m in Ser... |
| 28.11.2011 | CorMedix adds pharmaceutical veteran to board of directors | CorMedix (NYSE:CRMD), a Bridgewater, New Jersey-based therapeutic product developer for the prevention and treatment of cardiorenal disease, has added a pharmaceutical veteran to its board of directors.
Matt Duffy has worked for Pfizer (NYS... |
| 16.09.2009 | FDA approves four H1N1 flu vaccines, no shortage expected – MedCity Morning Read, Sept. 16, 2009 | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 29.10.2008 | BioLogix bags $6M for oncology drug, names new CEO | Biopharm company BioLogix raised $6 million in first-round equity and debt financing from Essex Woodlands Health Ventures and New Science Ventures. The money will be used to continue development of its top cancer-fighting compound, but a se... |
| 17.10.2008 | MedImmune expands R&D capacity with new research facility in Cambridge | MedImmune expands R&D capacity with new research facility in Cambridge
17-10-2008
MedImmune opens a new biologics research and development facility in Cambridge called the Aaron Klug Building. The building is named after the 1982 Nobel ... |
| 07.03.2008 | Life-science briefing: Friday, March 7, 2008 | TODAY’S HEADLINES:
Allegro pulls in $4M for lung-cancer molecular diagnostics (release)
Ocular bandage developer I-Therapeutix raises $6M (Mass High Tech)
NanoBio gets last of $30M for skin-infection drugs (release)
Cayenne Medical raises $... |
| 23.08.2007 | A biotech flu vaccine and the seduction of hype | (UPDATED: See below.)
Vaccine developer Protein Sciences is all over the blogosphere today (see, for instance, items on Pharmalot and the WSJ health blog), thanks to a breathless Bloomberg piece on the little Meriden, Conn., biotech. Accord... |
| 23.04.2007 | AstraZeneca ups the biotech ante | Now that AstraZeneca has made the bold — or impulsive — decision to snap up MedImmune for $15.6 billion in cash, one big question is whether the U.K. pharmaceutical giant has kicked Big Pharma’s appetite for biotech acquisitions into high g... |
| 16.04.2007 | Biotech financing: Are early-stage companies hot again? | Venture investors’ interest in early-stage biotech companies may finally be starting to revive, nearly six years after the collapse of a biotech-stock bubble quashed appetites for the industry’s riskiest but often most innovative companies.... |
| 16.04.2007 | Biotech financing: Are early-stage companies hot again? | (Note: This item has been copied over to the Life Sciences page from its original location on the VentureBeat main page. To view it in its original context, with comments, click here.)
Venture investors’ interest in early-stage biotech comp... |
| 19.07.2002 | US biotech firm MedImmune launches $100m venture fund | Their decision provides further evidence of the attractiveness of the biotech sector for venture investing. Dr Wayne T |
| - | CorMedix adds pharmaceutical veteran to board of directors | CorMedix (NYSE:CRMD), a Bridgewater, New Jersey-based therapeutic product developer for the prevention and treatment of cardiorenal disease, has added a pharmaceutical veteran to its board of directors.
Matt Duffy has worked for Pfizer (NYS... |
| - | Former head of Sanofi vaccines division becomes infectious disease biotech CEO | The former head of Sanofi’s (NYSE:SNY) vaccines division, one of the largest vaccine companies in the world, has joined a biotechnology company developing infectious disease vaccines as its CEO.
Wayne Pisano will lead Cranbury, New Jersey-b... |
| - | Biopharmaceutical firm NuPathe co-founder and CEO exits, enter former Auxilium head | Biopharmaceutical firm NuPathe’s (NASDAQ:PATH) CEO Jane Hollingsworth has resigned as CEO and board member of the company she co-founded more than six years ago. She has been replaced by the former CEO of Auxilium Pharmaceuticals (NASDAQ:AU... |
| - | AstraZeneca shakes up R&D division with 1,600 staff cuts and shift to biotech hot spots (video) | AstraZeneca (NYSE:AZN) is revamping its research and development divisions to improve drug development by cutting 1,600 from its global operations and focusing R&D staff in three sites including Gaithersburg, Maryland. It plans to ditch... |
| - | FDA approves four H1N1 flu vaccines, no shortage expected – MedCity Morning Read, Sept. 16, 2009 | Image via Wikipedia
WASHINGTON, D.C. – The U.S. Food and Drug Administration has approved four vaccines to guard against the H1N1 flu virus – and there will be enough doses to go around, Reuters reported Tuesday.
Health and Human Servi... |
